ArticleFrontiers in immunology2026
Sodium butyrate ameliorates intestinal motility and is associated with enteric neuroimmune changes in slow transit constipation mice.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The pathogenesis of slow transit constipation (STC) is still not fully elucidated, and there are no related specific drugs currently available for clinical use. Therefore, our study combined 16S ribosomal RNA (rRNA) gene sequencing, untargeted metabolomics, transcriptomic analysis, and a mouse intervention model to characterize the alterations associated with STC and to evaluate the effects of sodium butyrate (NaB). Methods: 16S rRNA gene sequencing, untargeted metabolomics, and RNA sequencing (RNA-seq) were performed in human samples. A loperamide-induced STC mouse model was established to evaluate the effects of NaB. Colonic tissues were assessed using hematoxylin-eosin (H&E) staining, Alcian blue staining, and immunohistochemistry, whereas longitudinal muscle and myenteric plexus preparations were used for immunofluorescence and quantitative reverse transcription PCR (qRT-PCR) analyses. Results: There were 16 differential bacterial genera between patients with STC and healthy donors. Untargeted metabolomics identified 71 exploratory candidate metabolites meeting variable importance in projection (VIP) > 1 and nominal Conclusion: NaB improved the constipation-related phenotypes in loperamide-induced STC mice and was accompanied by reduced inflammatory features, decreased myenteric neuronal apoptosis, and reduced neuronal pSTAT3 staining in the ENS. These findings suggest that the beneficial effects of NaB may be associated with the modulation of the enteric neuroimmune microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.